Pharmigene, Inc.
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test… Read more
Market Cap & Net Worth: Pharmigene, Inc. (7595)
Pharmigene, Inc. (TWO:7595) has a market capitalization of $15.86 Million (NT$524.84 Million) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #28477 globally and #1790 in its home market, demonstrating a -0.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmigene, Inc.'s stock price NT$10.40 by its total outstanding shares 50465000 (50.47 Million).
Pharmigene, Inc. Market Cap History: 2026 to 2026
Pharmigene, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $15.86 Million to $15.86 Million (0.00% CAGR).
Pharmigene, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmigene, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 7595 by Market Capitalization
Companies near Pharmigene, Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Pharmigene, Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Pharmigene, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Pharmigene, Inc.'s market cap moved from $15.86 Million to $ 15.86 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$15.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pharmigene, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.86 Million USD |
| MoneyControl | $15.86 Million USD |
| MarketWatch | $15.86 Million USD |
| marketcap.company | $15.86 Million USD |
| Reuters | $15.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.